Renal Failure News and Research RSS Feed - Renal Failure News and Research

Renal failure or kidney failure is where the kidneys fail to function adequately. Renal failure is divided in acute and chronic forms; either form may be due to a large number of other medical problems.
Pharmalink’s core patents for Nefecon issued in United States, Europe, China and Hong Kong

Pharmalink’s core patents for Nefecon issued in United States, Europe, China and Hong Kong

Pharmalink AB, a specialty pharma company focused on orphan and niche products, has had core patents for its late-stage clinical candidate Nefecon® issued in the key markets United States, Europe, China and Hong Kong. A patent is pending in Japan. [More]
Pain control in osteoarthritis patients: an interview with Dr. Clarence Young, Chief Medical Officer and John Vavricka, President and CEO, Iroko Pharmaceuticals

Pain control in osteoarthritis patients: an interview with Dr. Clarence Young, Chief Medical Officer and John Vavricka, President and CEO, Iroko Pharmaceuticals

Osteoarthritis (OA) is one of the most common causes of disability, and inadequate pain control can lead to joint stiffness that may impair mobility for patients. [More]
Acute kidney injury and chronic kidney disease are interconnected, say GW researchers

Acute kidney injury and chronic kidney disease are interconnected, say GW researchers

For more than 40 years, physicians have treated diminished kidney function as two distinct syndromes: acute kidney injury (AKI) and chronic kidney disease (CKD). However, recent epidemiologic and mechanistic studies suggest the two syndromes are not distinct entities, but interconnected. [More]
3SBio signs exclusive license agreement with Selecta Biosciences for pegsiticase

3SBio signs exclusive license agreement with Selecta Biosciences for pegsiticase

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with Selecta Biosciences for pegsiticase (Uricase PEG-20), a pegylated recombinant uricase from candida utilis. [More]
FDA accepts Pharmacyclics' IMBRUVICA sNDA for review

FDA accepts Pharmacyclics' IMBRUVICA sNDA for review

Pharmacyclics, Inc. today announced that the U.S. Food and Drug Administration has accepted for filing its supplemental New Drug Application (sNDA) to support the review of IMBRUVICA (ibrutinib) in the treatment of patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) who have received at least one prior therapy for a full approval. [More]
Amgen presents extended analysis of PEAK study data at ASCO

Amgen presents extended analysis of PEAK study data at ASCO

Amgen today announced results from the Phase 2 PEAK study that reinforce the improved overall survival (OS) benefit of panitumumab (Vectibix®) when used in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, compared to bevacizumab (Avastin) plus FOLFOX as first-line treatment in patients with wild-type RAS metastatic colorectal cancer (mCRC). [More]
Sanofi presents Phase II trial results for investigational vaccine for prevention of CDI

Sanofi presents Phase II trial results for investigational vaccine for prevention of CDI

Sanofi Pasteur, the vaccines division of Sanofi, presented Phase II (H-030-012) trial results for an investigational vaccine for the prevention of Clostridium difficile infection at the 114th General Meeting of the American Society for Microbiology. [More]
Researchers find links between hospital readmission rates and social factors

Researchers find links between hospital readmission rates and social factors

Factors like the level of poverty in a neighborhood, living alone, and age affect a patient's chances of being readmitted to a hospital after discharge, even after possible variations in quality of care in the hospital have been taken into account. [More]
Life expectancy after diabetic complications gauged

Life expectancy after diabetic complications gauged

Researchers have generated an equation to estimate the probable life expectancies of patients with diabetes who experience a major complication. [More]
Adhesion molecule offers promising therapeutic target for preventing colitis

Adhesion molecule offers promising therapeutic target for preventing colitis

May Provide Therapeutic Target for Treating Inflammatory Bowel Disease and Preventing Colitis-Associated Colorectal Cancer, According to New Research Published in The American Journal of Pathology [More]
Concert Pharmaceuticals reports results from CTP-499 Phase 2 trial in patients with diabetic kidney disease

Concert Pharmaceuticals reports results from CTP-499 Phase 2 trial in patients with diabetic kidney disease

Concert Pharmaceuticals, Inc. today announced 48-week results of its Phase 2 clinical trial of CTP-499 in patients with diabetic kidney disease. CTP-499, when used in addition to the standard of care, is being developed to delay the progression of these patients to end-stage renal failure, which requires dialysis or kidney transplantation. [More]

Novel method could help kidney stone sufferers receive correct, effective treatment

Researchers in France have hit on a novel method to help kidney stone sufferers ensure they receive the correct and most effective treatment possible. [More]
NEPHRON+ project improves lives of kidney failure patients by developing wearable artificial kidney device

NEPHRON+ project improves lives of kidney failure patients by developing wearable artificial kidney device

End stage kidney disease is a global public health problem with an estimated 2.4 million patients on dialysis. The number of new cases is rising (7-8% annually) due to population ageing and increased diabetes prevalence. [More]
Students competing in Center for Medical Innovation’s Annual Bench-to-Bedside Competition win nearly $72,000

Students competing in Center for Medical Innovation’s Annual Bench-to-Bedside Competition win nearly $72,000

University of Utah students competing in the Center for Medical Innovation's Annual Bench-to-Bedside Competition were awarded nearly $72,000 in prize money on April 9 at the Utah State Capitol. [More]
Janssen submits supplemental New Drug Application for IMBRUVICA to the U.S. FDA

Janssen submits supplemental New Drug Application for IMBRUVICA to the U.S. FDA

Janssen Research & Development, LLC ("Janssen") today announced the submission of a supplemental New Drug Application (sNDA) for IMBRUVICA™ (ibrutinib) to the U.S. Food and Drug Administration (FDA) by its collaboration partner Pharmacyclics, Inc. [More]
Study shows administering steroids during cardiac surgery requiring bypass can cause harm

Study shows administering steroids during cardiac surgery requiring bypass can cause harm

Giving patients steroids at the time of heart surgery does not improve health outcomes and appears to put them at greater risk of having a heart attack in the days following surgery, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session. [More]
Bariatric surgery more effective than intensive medical therapy for managing type 2 diabetes

Bariatric surgery more effective than intensive medical therapy for managing type 2 diabetes

​Gastric bypass and sleeve gastrectomy - two of the most commonly used bariatric surgeries - are more effective than intensive medical therapy alone when it comes to managing uncontrolled type 2 diabetes in overweight or obese patients after three years, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session. [More]
Study: Repeat sternotomy for surgical aortic valve replacement safe for octogenarian patients

Study: Repeat sternotomy for surgical aortic valve replacement safe for octogenarian patients

Surgical aortic valve replacement generally improves patients' symptoms and prolongs survival. However, the perceived risk of surgical aortic valve replacement in patients over 80 may result in surgery being denied or a recommendation for alternative therapy. Investigators at the Mayo Clinic challenge the way these patients have been managed. [More]

Nephros’ total revenues decrease $67,000 to 4% in the year ended December 31, 2012

Nephros, Inc., a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for the treatment of chronic renal failure patients, announced today financial results for the three months and full year ended December 31, 2013. [More]

Study lays groundwork for PET imaging studies on human Menkes disease

Scientists at the RIKEN Center for Life Science Technologies have used PET imaging to visualize the distribution in the body of copper, which is deregulated in Menkes disease, a genetic disorder, using a mouse model. This study lays the groundwork for PET imaging studies on human Menkes disease patients to identify new therapy options. [More]